4SC to Present at Sal. Oppenheim, Rodman & Renshaw and DZ Bank Investor Conferences
August 31 - CFO Enno Spillner presents at the Sal. Oppenheim European Healthcare Conference 2009, Frankfurt, Germany at 5.25pm local time.
September 9 - CEO Ulrich Dauer presents at Rodman and Renshaw Annual Global Investment Conference, New York, USA at 2.25pm local time.
September 11 - CDO Bernd Hentsch presents at the DZ Bank German Healthcare Conference, Zurich, Switzerland, at 3.05pm local time.
This document may contain projections or estimates relating to plans and objectives relating to our future operations, products, or services; future financial results; or assumptions underlying or relating to any such statements; each of which constitutes a forward-looking statement subject to risks and uncertainties, many of which are beyond our control. Actual results could differ materially, depending on a number of factors.
4SC AG (ISIN DE0005753818) is a drug discovery and development company focused on autoimmune and cancer indications. The company currently has three clinical programs, with three further clinical trials planned to commence in 2009. The lead autoimmune compound, 4SC-101, is in a Phase IIa trial in Crohn's disease and is due to commence a Phase IIb trial in rheumatoid arthritis in 2009. The lead oncology compound, 4SC-201, is in a Phase II trial in hepatocellular carcinoma (HCC) and is due to commence a further Phase II trial in Hodgkin's lymphoma in 2009. Drug candidates are developed until proof-of-concept and subsequently partnered with the pharmaceutical industry in return for advance and milestone payments as well as royalties.
4SC was founded in 1997, has 92 employees, and is listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.